One approach stimulates your own pituitary through two pathways. The other replaces the hormone directly. Here's the full comparison of mechanisms, outcomes, and research tradeoffs.
CJC-1295 / Ipamorelin stimulates your own pituitary to release GH through two complementary receptor pathways — preserving natural pulsatile release and feedback loops. Exogenous HGH replaces GH directly, producing flat supraphysiological levels that bypass all natural regulation. The peptide stack is more physiological, lower cost, and avoids pituitary suppression. Direct HGH produces higher, more controllable GH levels and has more extensive clinical data. Neither is superior in every context — they serve different research goals.
The peptide stack works upstream of GH itself. CJC-1295 (Mod GRF 1-29) binds GHRH receptors on the pituitary, triggering GH synthesis and release. Ipamorelin binds ghrelin receptors, providing a second independent stimulatory signal while suppressing somatostatin (the GH inhibitor). The resulting GH pulse is produced by the pituitary from its own stores — subject to normal feedback regulation. When GH and IGF-1 rise sufficiently, they signal the hypothalamus to reduce GHRH output and increase somatostatin, naturally capping the response.
Synthetic HGH (recombinant human growth hormone, rhGH) is injected directly into circulation. It bypasses all upstream regulation entirely — no hypothalamus involvement, no pituitary involvement. GH levels rise in proportion to the dose injected and remain elevated for hours in a flat, non-pulsatile pattern. The normal feedback system still responds (elevated GH suppresses endogenous GHRH output), which is why long-term HGH use can suppress the pituitary's own GH-producing capacity.
Endogenous GH is released in pulses — the largest during deep sleep, smaller ones throughout the day. These pulses matter for downstream signaling: pulsatile GH produces different tissue responses than constant elevation. Some GH receptors downregulate with sustained exposure (flat HGH pattern) while responding more robustly to pulsed signals. Whether this difference is clinically meaningful at typical research doses is debated, but it's the physiological argument for preferring pulsatile stimulation.
| Factor | CJC-1295 / Ipamorelin | Exogenous HGH |
|---|---|---|
| Mechanism | Stimulates endogenous GH release | Replaces GH directly |
| GH pattern | Pulsatile (physiological) | Flat, sustained (supraphysiological) |
| Feedback loop | Preserved | Bypassed |
| Pituitary suppression risk | Low — pituitary remains active | Higher with long-term use |
| IGF-1 response | Moderate, natural range | Direct, dose-dependent — can exceed natural range |
| Cost | Significantly lower | Substantially higher |
| Dosing frequency | 1–3x daily SubQ | Once daily SubQ (typical) |
| Side effect profile | Milder — within physiological GH range | More pronounced at higher doses (edema, joint pain, CTS) |
| Clinical history | Ipamorelin: research compound. CJC: research | Extensive — decades of clinical use |
| Regulatory status | Research compounds | FDA approved for specific indications |
| Research Goal | Lean Toward | Rationale |
|---|---|---|
| GH optimization within physiological range | CJC / Ipamorelin | Preserves feedback, pulsatile pattern, lower cost |
| Maximum GH / IGF-1 elevation | HGH | Direct replacement allows higher, controllable GH levels |
| Pituitary health / no suppression concern | CJC / Ipamorelin | Pituitary remains active; no suppression of endogenous function |
| Established long-term safety data | HGH | Decades of clinical use data vs research compound status |
| Cost-sensitive protocol | CJC / Ipamorelin | Substantially lower cost per cycle |
| Pediatric GH deficiency (clinical) | HGH | FDA-approved indication; recombinant HGH is standard of care |
COA-verified vendor pricing with promo codes from S1 Research and Tegridy Research.
View Pricing → Dosage Calculator